Vanguard Asset Management
TARS icon

Vanguard Asset Management’s Tarsus Pharmaceuticals TARS Stock Holding History

Vanguard Asset Management’s Portfolio TARS Stock Details TARS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.31M Hold
20,748
– – ﹤0.01% 1756
2026
Q1 		$1.46M Buy
+20,748
New +$1.45M ﹤0.01% 1608

Other funds holding TARS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Vanguard Asset Management's TARS Position: Q2 2026 in Review

Vanguard Asset Management held its Tarsus Pharmaceuticals (TARS) position steady in Q2 2026 at 20,748 shares worth $1.31M. The position accounts for ﹤0.01% of the portfolio, ranked #1756.

Vanguard Asset Management first reported a position in TARS in Q1 2026 and has held it in 2 quarters since. The position peaked at $1.46M in Q1 2026. 254 funds tracked by Wall St. Rank hold TARS as of Q2 2026.

  • Vanguard Asset Management held 20,748 shares of Tarsus Pharmaceuticals worth $1.31M as of Q2 2026.
  • Vanguard Asset Management left its Tarsus Pharmaceuticals share count unchanged in Q2 2026.
  • Tarsus Pharmaceuticals made up ﹤0.01% of Vanguard Asset Management's portfolio in Q2 2026, its #1756 holding.
  • Vanguard Asset Management first reported a position in Tarsus Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • Vanguard Asset Management's Tarsus Pharmaceuticals position peaked at $1.46M in Q1 2026.
  • 254 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q2 2026.

Based on Vanguard Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.